Overview

Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement

Status:
Completed

Trial end date:
2009-01-01

Target enrollment:

Participant gender:

Summary

Researchers from the Division of Pulmonary and Critical Care Medicine at University of California, San Francisco (UCSF) are conducting a study to evaluate whether mycophenolate mofetil (an immunosuppressive medication, trade named CellCept) is safe and effective for preventing the lung damage from scleroderma from getting worse.

Phase:

N/A

Details

Lead Sponsor:

University of California, San Francisco

Collaborator:

Roche Pharma AG

Treatments:

Mycophenolate mofetil
Mycophenolic Acid